Navigation Links
Corgenix Reports Second Quarter Fiscal 2009 Financial Results
Date:2/12/2009

- Revenues for the quarter decrease 17% vs. prior year -

DENVER, Feb. 12 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its 2nd quarter Form 10-Q and reported financial results. The report disclosed that the company's sales and operating results have declined during the quarter and six months ended December 31, 2008. Some of the results highlighted by the report are as follows:

  • Revenues for the quarter decreased $404,012 or 16.8% vs. the prior year's comparable quarter; of this, $179,365 was a reduction in contract manufacturing revenue primarily due to reduced sales to one key customer as previously reported.
  • Total operating expenses increased $88,345 or 7.9% vs. the prior year's comparable quarter.
  • Operating loss for the quarter was $56,223 vs. an operating income of $224,224 for the prior year's comparable quarter.
  • Net loss increased to $268,374 in the current quarter from $60,310 in the prior year's comparable quarter.

"The decline in our revenues continues to demonstrate the weakness in our contract manufacturing sector as previously reported," said Douglass Simpson, President and CEO of Corgenix. "Excluding contract manufacturing revenue, our six month revenues declined approximately 3.5% over the same period in the prior year which we believe is largely related to the slowdown of the overall economy. We are continuing to aggressively seek opportunities to grow our business in contract manufacturing as well as our core products including the AspirinWorks Test."

The company noted that the financial performance for the quarter was weak, with weakness in core product revenue and increased net negative cash flow. The company expects that Fiscal Year 2009 revenues will approximate that of the prior fiscal year.

Second Quarter 2009 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of second quarter results to join a shareholders conference call on Thursday, February 12, 2009 at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing (800) 862-9098. International participants may access the call by dialing +1 785-424-1051. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 723-5782 for domestic participants and +1 402-220-2663 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.


                            SUMMARY OF FINANCIAL HIGHLIGHTS
      ($000 of U.S. dollars except shares outstanding and per share amounts)

                      CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES
                                    OPERATIONAL DATA

                        Three Months Ended              Six Months Ended
                        ------------------              ----------------

                    December 31,   December 31,   December 31,   December 31,
                       2008           2007           2008           2007
                    (unaudited)    (unaudited)    (unaudited)    (unaudited)

    Net sales            $1,995         $2,399         $3,997         $4,504
    Gross profit          1,154          1,346          2,261          2,487
    Total operating
     expenses             1,210          1,122          2,411          2,261
    Operating income
     (loss)                 (56)           224           (150)           226
    Net loss               (268)           (60)          (609)          (748)
    Basic and diluted
     loss per share      $(0.01)        $(0.00)        $(0.02)        $(0.03)
    Diluted shares
     outstanding     30,280,155     25,048,943     30,186,124     22,179,066



                                SUMMARY BALANCE SHEET DATA
                                      (in thousands)

                               December 31, 2008           June 30, 2008
                                   (unaudited)               (audited)

    Cash                                   $731                  $1,520
    Working capital                       2,268                   2,889
    Total assets                          6,790                   7,888
    Long-term debt                          943                   1,276
    Total stockholders' equity            3,636                   4,153


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Corgenix Signs Technology Licensing Agreement With Japanese Government
2. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
3. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
4. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
6. Corgenix Expands Scientific Advisory Board
7. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
8. Corgenix Reports Fiscal 2008 Financial Results
9. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
10. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
11. Corgenix to Host Conference Call to Discuss First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 05, 2016 , ... CereScan, the nation’s leader in providing ... National Stroke Awareness Month in May. An infographic created by CereScan will ... CereScan will donate $1 up to a maximum of $3,000 through users who ...
(Date:5/4/2016)... ALBANY, New York , May 4, 2016 /PRNewswire/ ... published by Transparency Market Research "Metabolomics Market - Global ... - 2024", the metabolomics market is anticipated to expand ... to reach USD 2,494.8 million by 2024. ... known as metabolites, within cells, biofluids, tissues or organisms. ...
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published by ... the state’s 76 fastest-growing private companies; a small percentage of the state's 615,000+ small ... on the percent change in revenue from 2012 to 2015. , As ...
(Date:5/3/2016)... -- - And Other Rising Companies - ... Competitor Biologics  - Biosimilar Drug Producers - ... Who are the most important and promising ... sales potentials? Discover, in our updated survey, organisations, outlooks ... revenue forecasting. Visiongain,s new study ...
Breaking Biology Technology:
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
Breaking Biology News(10 mins):